P3 Health Partners Appoints Dr. Michael Millie as Chief Clinical Officer
P3 Health Partners, a patient-centered, physician-led population health management company, has announced the appointment of Dr. Michael Millie as its new Chief Clinical Officer, effective October 12, 2026. The appointment brings an experienced physician executive into a senior clinical leadership role as the company continues its focus on population health management and value-based care.
Dr. Millie most recently served as a Chief Medical Officer, where he oversaw clinical operations and value-based care programs. His professional background combines medical training, physician leadership and business education, providing experience across clinical decision-making and healthcare management. He earned his Doctor of Medicine degree from the University of Nebraska Medical Center and holds a Master of Business Administration from the University of Washington. He also trained as a surgeon.
The appointment places Dr. Millie in a key leadership position at P3 Health Partners, where clinical leadership is central to the company’s physician-led approach to healthcare delivery. His experience overseeing clinical and value-based care programs is relevant to an organization focused on population health management, which emphasizes coordinating services and addressing the healthcare needs of defined patient populations.
Alongside the leadership announcement, P3 disclosed that its Compensation and Nominating Committee approved a non-qualified stock option award for Dr. Millie. The award was granted as a material inducement to his employment and was approved under Nasdaq Listing Rule 5635(c)(4), which governs certain equity awards made outside stockholder-approved compensation plans to individuals entering employment with a company.
Dr. Michael Millie Brings Physician Executive Experience
Dr. Millie’s appointment reflects the importance of clinical leadership within healthcare organizations that manage care for patient populations. In a Chief Clinical Officer role, leadership responsibilities may involve supporting clinical strategy, aligning healthcare delivery with organizational objectives and overseeing initiatives intended to improve the coordination of patient care.
According to the company’s announcement, Dr. Millie most recently served as a Chief Medical Officer, overseeing clinical and value-based care programs. This background is particularly relevant to P3’s operating model, which places physicians at the center of population health management.
Physician executives often work across multiple areas of healthcare operations. These can include clinical program oversight, care coordination, provider engagement and the development of approaches that support quality and efficiency. Their work can also involve collaborating with administrative and operational leaders to ensure that organizational priorities align with clinical needs.
Dr. Millie’s medical education at the University of Nebraska Medical Center provided the foundation for his career in medicine, while his surgical training adds to his clinical background. His MBA from the University of Washington complements that experience with formal business education.
The combination of clinical and business knowledge can be useful in senior healthcare leadership positions, where decisions often require consideration of patient needs, provider workflows, operational processes and financial sustainability.
P3’s announcement identifies Dr. Millie as a proven physician executive, highlighting his previous experience overseeing clinical and value-based care programs. Although the company did not provide additional details about his specific responsibilities at P3, his appointment establishes him as a senior clinical leader within the organization.
Clinical Leadership and Population Health Management
Population health management focuses on improving the health outcomes of groups of patients rather than concentrating exclusively on individual medical encounters. Depending on the care model, it may involve identifying patients who need additional support, coordinating services across healthcare settings, managing chronic conditions and encouraging preventive care.
These approaches require coordination among physicians, care teams, healthcare organizations and administrative staff. Clinical leaders can help establish priorities, guide care delivery programs and support the implementation of practices designed to meet patient needs.
For physician-led organizations such as P3 Health Partners, clinical leadership is particularly relevant because physicians play a central role in the company’s approach to managing healthcare. A senior clinical executive can help connect the perspectives of practicing clinicians with broader organizational goals.
Value-based care is closely associated with this approach. Unlike traditional payment arrangements that primarily emphasize the volume of services delivered, value-based care models generally place greater emphasis on the quality, outcomes and overall cost of care. The specific arrangements vary, but they can create incentives to improve care coordination, manage preventable complications and provide appropriate services at the right time.
Successfully operating within these models requires clinical oversight as well as the ability to work with healthcare data, providers and operational teams. Organizations must consider how to deliver appropriate care while meeting quality expectations and managing available resources.
Dr. Millie’s previous experience overseeing value-based care programs gives him a professional background relevant to these operational challenges. His appointment may support P3’s ongoing clinical leadership needs, although the company has not announced specific new initiatives or strategic changes associated with his arrival.
A Leadership Role Within P3 Health Partners
P3 Health Partners describes itself as a patient-centered and physician-led population health management company. Its stated approach places emphasis on healthcare delivery that considers patients’ needs while using population health management and value-based care programs.
Within this context, the Chief Clinical Officer position is an important senior role. Clinical leadership can help ensure that the medical perspective is represented in organizational planning and that care programs are designed around clinical priorities.
The position may also require collaboration across functions. Healthcare organizations often need clinical executives to work with physicians, operational teams and other leaders to coordinate care strategies and support the implementation of clinical programs.
The relationship between clinical quality and operational performance is particularly important in population health management. Patients may receive services from multiple providers and healthcare settings, making coordination essential to maintaining continuity of care.
Senior clinical leadership can help organizations assess whether their care models support consistent treatment, appropriate follow-up and communication among providers. It can also contribute to efforts to identify gaps in care and develop approaches to address the needs of patients who require additional assistance.
P3’s announcement did not outline changes to its existing clinical programs, operating structure or business strategy following Dr. Millie’s appointment. However, the appointment adds a physician executive with prior experience in clinical and value-based care oversight to the company’s leadership team.
Stock Option Award Approved as an Employment Inducement
In addition to announcing the appointment, P3 Health Partners disclosed the approval of a non-qualified stock option for Dr. Millie. The company’s Compensation and Nominating Committee authorized the award as a material inducement to his employment.
According to the announcement, Dr. Millie was not previously an employee or director of P3 Health Partners. The company therefore granted the option under an employment inducement arrangement rather than through its existing stockholder-approved equity compensation plan.
The option gives Dr. Millie the right to purchase 110,000 shares of P3’s Class A common stock, subject to the terms of the award. Its exercise price per share is equal to the closing price of P3’s Class A common stock on the grant date, October 12, 2026.
The option has a term of ten years. This means the award may remain exercisable during the specified term, subject to the agreement’s conditions and any applicable provisions governing its exercise or termination.
The option will vest in four equal annual installments, provided Dr. Millie continues to provide services to P3. Specifically, 25% of the underlying shares will vest and become exercisable on each of the first four anniversaries of the grant date.
Based on the 110,000 shares covered by the award, each annual installment represents 27,500 shares. The schedule links the vesting of the award to continued service with the company over four years.
Vesting determines when an employee earns the right to exercise an equity award, subject to its terms. A stock option does not itself represent an immediate purchase of shares, nor does it guarantee a financial gain. Its potential value depends on factors including the company’s share price, the exercise price, the option’s term and the conditions attached to the award.
The award’s ten-year term establishes its stated duration, while the four-year vesting schedule determines when the underlying options become exercisable. The applicable award agreement governs the detailed conditions.
Compliance With Nasdaq Listing Requirements
P3 stated that the stock option was approved in accordance with Nasdaq Listing Rule 5635(c)(4). The rule addresses equity awards granted as material inducements to individuals entering employment with a company, including certain awards that are not made under a stockholder-approved equity compensation plan.
Under the company’s disclosure, the award was approved by the Compensation and Nominating Committee of P3’s Board of Directors. The announcement also fulfills the public disclosure requirement identified by the company for equity awards granted under this provision.
The option was issued as a stand-alone inducement award outside the P3 Health Partners Inc. 2021 Incentive Award Plan. However, P3 noted that the award is generally subject to the same terms and conditions that apply to awards granted under that plan.
Inducement awards can be used by companies as part of the compensation offered to new employees. Equity-based compensation may align a portion of an employee’s potential financial interests with the company’s stock performance over time. The actual financial outcome depends on the terms of the award and subsequent market conditions.
In Dr. Millie’s case, the award is tied to continued service through a four-year vesting schedule. This structure means the full option does not vest immediately upon his appointment.
The company disclosed the number of shares covered by the option, its exercise price mechanism, the grant date, its ten-year term and its annual vesting schedule. These details provide shareholders and other market participants with information about the equity award associated with the new executive’s employment.
What the Appointment Means for the Company
The appointment of Dr. Millie adds senior physician leadership to P3 Health Partners at a time when population health management and value-based care remain important areas of healthcare delivery.
These models require organizations to balance clinical priorities with the operational demands of coordinating care for groups of patients. Physician executives can contribute clinical experience to decisions involving care delivery, provider relationships and program oversight.
Dr. Millie’s background as a surgeon, his previous experience as a Chief Medical Officer and his oversight of clinical and value-based care programs provide the professional foundation described in the announcement. His medical degree and business administration education also represent a combination of clinical and management training.
The company has not disclosed additional details about his specific responsibilities, future clinical priorities or any planned changes to existing programs. Consequently, the immediate confirmed developments are his appointment, effective October 12, 2026, and the associated inducement stock option award.
For investors, the announcement also provides information about the compensation arrangement accompanying the appointment. The option’s structure, including its exercise price, term and vesting schedule, is relevant to understanding the company’s disclosed employment inducement.
P3 Health Partners Inc. has appointed Dr. Michael Millie as Chief Clinical Officer, effective October 12, 2026. Dr. Millie brings physician executive experience, a background in surgery and prior responsibility for clinical and value-based care programs. His medical degree from the University of Nebraska Medical Center and MBA from the University of Washington complement his professional experience.
The appointment reinforces the role of physician leadership within P3’s patient-centered population health management model. Alongside the leadership change, the company approved a non-qualified stock option covering 110,000 shares of Class A common stock as a material inducement to Dr. Millie’s employment. The award has a ten-year term and vests in four equal annual installments, subject to continued service.
Together, the disclosures outline both the executive appointment and the associated compensation arrangement as P3 continues its work in population health management and value-based care.
Source link: https://ir.p3hp.org/
